GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Since 2012, when Truvada was first approved as a preventative treatment for HIV, Gilead has had a monopoly on PrEP, or pre-exposure prophylaxis. Now, in a large NIH-backed trial, a new drug from a pair of Big Pharma rivals looked just as effective, if not more.
Investigators tested a long acting injectable from ViiV Healthcare — the joint HIV initiative between Pfizer and GlaxoSmithKline — against Truvada across 4,600 people at risk for HIV infection. The trial, although only powered for non-inferiority, showed those on the long-acting injectable were 69% less likely to contract HIV than those on Truvada, a once-daily pill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
